NCT03988634: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03988634 |
|---|---|
| Title | A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Valsartan on Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 29, 2019 |
| Completion date | Dec. 14, 2022 |
| Required reporting date | Dec. 14, 2023, midnight |
| Actual reporting date | Nov. 22, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |